BiPar Sciences' Series C Round

BiPar Sciences raised a round of funding on January 23, 2009.

BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including t…

Articles about BiPar Sciences' Series C Round: